Advertisement
U.S. markets close in 58 minutes

ValiRx plc (EAJF.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.01950.0000 (0.00%)
As of 09:11AM CET. Market open.

ValiRx plc

Stonebridge House
Chelmsford Road Hatfield Heath
England CM22 7BD
United Kingdom

https://www.valirx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

NameTitlePayExercisedYear Born
Mr. James Gerry Desler FCACFO, Company Secretary & Executive Director78.81kN/A1945
Mr. Kumar NawaniHead of OperationsN/AN/AN/A
Dr. Catherine Jane Tralau-Stewart Ph.D.Executive Director, Chief Scientific Officer & Board OfficerN/AN/AN/A
Mr. Mark TreharneCorporate Development ManagerN/AN/AN/A
Dr. Andrew CarnegieHead of Strategic Commercial DevelopmentN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.

Corporate Governance

ValiRx plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.